XtalPi Holdings (HKEX: 2228) reported full-year 2025 income of roughly $112 million (RMB 803 million), up 201.2% year-on-year, marking its first annual revenue.
Internet revenue reached $19 million (RMB 135 million), whereas adjusted internet revenue was about $36 million (RMB 258 million). The corporate stated it’s the first worthwhile publicly listed firm within the AI for Science sector.
Development was pushed by sturdy demand for drug discovery options and broader AI-for-science providers. Income from drug discovery rose 418.9% to $75 million, whereas AI-for-science options elevated 62.6% to about $37 million.
By the tip of 2025, XtalPi had expanded its buyer base by 62% year-on-year, serving 17 of the world’s high 20 pharmaceutical corporations, with cumulative contract worth reaching into the tens of billions of yuan. The corporate reported money reserves of $990 million (RMB 7.07 billion), with an extra $360 million (RMB 2.56 billion) raised by way of convertible bonds in 2026.
XtalPi has superior greater than 5 first-in-class or best-in-class drug pipelines into scientific or IND-enabling levels, spanning oncology, autoimmune ailments, and neurodegenerative problems. The corporate has additionally expanded into new sectors together with vitality and shopper well being.
So far, it has developed over 200 trade AI fashions, with autonomous brokers operating tens of hundreds of compound synthesis experiments weekly. In 2025, XtalPi was added to a number of indices, together with the MSCI China Index.
Supply: IPOzaozhidao
Elevate your perspective with NextTech Information, the place innovation meets perception.
Uncover the newest breakthroughs, get unique updates, and join with a worldwide community of future-focused thinkers.
Unlock tomorrow’s traits immediately: learn extra, subscribe to our e-newsletter, and develop into a part of the NextTech group at NextTech-news.com
